MX2016006591A - Agentes anticancerosos y sus preparaciones. - Google Patents
Agentes anticancerosos y sus preparaciones.Info
- Publication number
- MX2016006591A MX2016006591A MX2016006591A MX2016006591A MX2016006591A MX 2016006591 A MX2016006591 A MX 2016006591A MX 2016006591 A MX2016006591 A MX 2016006591A MX 2016006591 A MX2016006591 A MX 2016006591A MX 2016006591 A MX2016006591 A MX 2016006591A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- cancer agents
- compounds
- splenicosome
- epoxyalcohol
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 238000005649 metathesis reaction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyrane Compounds (AREA)
- Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Las formas de realización de la presente invención proporcionan, entre otros compuestos, una familia de compuestos que inhiben el espliceosoma que se pueden utilizar como agentes terapéuticos anticancerosos. Los compuestos se sintetizan en un proceso que incluye la metátesis catalítica cruzada de un epoxialcohol cíclico en una amida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361906133P | 2013-11-19 | 2013-11-19 | |
| PCT/US2014/066458 WO2015077370A1 (en) | 2013-11-19 | 2014-11-19 | Anti-cancer agents and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016006591A true MX2016006591A (es) | 2017-05-30 |
| MX375896B MX375896B (es) | 2025-03-07 |
Family
ID=53180106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006591A MX375896B (es) | 2013-11-19 | 2014-11-19 | Agentes anticancerosos y sus preparaciones. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10000505B2 (es) |
| EP (1) | EP3071563B1 (es) |
| JP (2) | JP6937578B2 (es) |
| KR (1) | KR102428737B1 (es) |
| CN (3) | CN113773333A (es) |
| AU (1) | AU2014353087B2 (es) |
| BR (1) | BR112016011430B1 (es) |
| CA (1) | CA2931111C (es) |
| CL (1) | CL2016001209A1 (es) |
| DK (1) | DK3071563T3 (es) |
| EA (1) | EA035262B1 (es) |
| ES (1) | ES2943711T3 (es) |
| FI (1) | FI3071563T3 (es) |
| IL (2) | IL282430B2 (es) |
| MX (1) | MX375896B (es) |
| MY (1) | MY189459A (es) |
| PE (1) | PE20161240A1 (es) |
| PH (2) | PH12021551085A1 (es) |
| PT (1) | PT3071563T (es) |
| WO (1) | WO2015077370A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3071563B1 (en) * | 2013-11-19 | 2023-04-19 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
| WO2017214423A2 (en) * | 2016-06-08 | 2017-12-14 | William Marsh Rice University | Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof |
| EP3515492B1 (en) | 2016-09-23 | 2023-07-26 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
| IL302943A (en) | 2017-09-20 | 2023-07-01 | Ph Pharma Co Ltd | Thylanstatin analogs |
| CN109020876A (zh) * | 2018-09-21 | 2018-12-18 | 大连理工大学 | 一种新型6-羟基-2h-二氢吡啶-3-酮的制备方法 |
| CN120189526A (zh) | 2018-12-13 | 2025-06-24 | 卫材R&D管理有限公司 | 荷伯希二烯抗体-药物缀合物及使用方法 |
| JP2023521135A (ja) * | 2020-04-09 | 2023-05-23 | ブリストル－マイヤーズ スクイブ カンパニー | メアヤマイシン類似体および使用方法 |
| CN113563361B (zh) * | 2021-08-17 | 2022-05-20 | 浙江珲达生物科技有限公司 | 一种从伯克霍尔德菌发酵液提取fr901464的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901464A (fr) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Procédé d'obtention de vanilline |
| US7825267B2 (en) * | 2006-09-08 | 2010-11-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of FR901464 and analogs with antitumor activity |
| AU2009225877B2 (en) | 2008-03-18 | 2014-11-20 | Genentech, Inc. | Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| AR080234A1 (es) * | 2010-02-25 | 2012-03-21 | Marrone Bio Innovations Inc | Cepa bacteriana aislada del genero burkholderia y metabolitos pesticidas del mismo |
| CA2845732C (en) * | 2011-08-27 | 2019-07-16 | Marrone Bio Innovations, Inc. | Isolated bacterial strain of the genus burkholderia and pesticidal metabolites therefrom-formulations and uses |
| PL2917195T3 (pl) * | 2012-11-05 | 2018-04-30 | Pfizer Inc. | Analogi spliceostatyny |
| EP3071563B1 (en) | 2013-11-19 | 2023-04-19 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
-
2014
- 2014-11-19 EP EP14863201.1A patent/EP3071563B1/en active Active
- 2014-11-19 FI FIEP14863201.1T patent/FI3071563T3/fi active
- 2014-11-19 ES ES14863201T patent/ES2943711T3/es active Active
- 2014-11-19 JP JP2016532025A patent/JP6937578B2/ja active Active
- 2014-11-19 WO PCT/US2014/066458 patent/WO2015077370A1/en not_active Ceased
- 2014-11-19 AU AU2014353087A patent/AU2014353087B2/en active Active
- 2014-11-19 DK DK14863201.1T patent/DK3071563T3/da active
- 2014-11-19 KR KR1020167016232A patent/KR102428737B1/ko active Active
- 2014-11-19 IL IL282430A patent/IL282430B2/en unknown
- 2014-11-19 MY MYPI2016000932A patent/MY189459A/en unknown
- 2014-11-19 PH PH1/2021/551085A patent/PH12021551085A1/en unknown
- 2014-11-19 BR BR112016011430-2A patent/BR112016011430B1/pt active IP Right Grant
- 2014-11-19 PE PE2016000653A patent/PE20161240A1/es unknown
- 2014-11-19 CA CA2931111A patent/CA2931111C/en active Active
- 2014-11-19 PT PT148632011T patent/PT3071563T/pt unknown
- 2014-11-19 CN CN202110798234.5A patent/CN113773333A/zh active Pending
- 2014-11-19 US US15/038,027 patent/US10000505B2/en active Active
- 2014-11-19 MX MX2016006591A patent/MX375896B/es active IP Right Grant
- 2014-11-19 CN CN202110798232.6A patent/CN113461705A/zh active Pending
- 2014-11-19 CN CN201480070416.9A patent/CN105829299A/zh active Pending
- 2014-11-19 EA EA201691010A patent/EA035262B1/ru not_active IP Right Cessation
-
2016
- 2016-05-15 IL IL245637A patent/IL245637B/en active IP Right Grant
- 2016-05-19 CL CL2016001209A patent/CL2016001209A1/es unknown
- 2016-05-19 PH PH12016500924A patent/PH12016500924A1/en unknown
-
2019
- 2019-07-05 JP JP2019125655A patent/JP6929903B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016006591A (es) | Agentes anticancerosos y sus preparaciones. | |
| ECSP24031979A (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| CL2017003404A1 (es) | Compuestos antibacterianos | |
| DOP2018000257A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| MX2015010312A (es) | Metodos para tratamiento del melanoma. | |
| DOP2016000145A (es) | Reguladores de nrf2 | |
| CO2017013709A2 (es) | Lactamas bicíclicas. | |
| CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
| CL2016003056A1 (es) | Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer. | |
| NI201400079A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| GT201400142A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CL2016001509A1 (es) | Formas cristalinas de los análogos de sofosbuvir antivirales | |
| MX379193B (es) | Composiciones en solucion solida y su uso en inflamacion cronica. | |
| MX2017017157A (es) | Composiciones de bebida lista para beber estables que comprende agentes activos lipofilos. | |
| AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
| MX336741B (es) | Composiciones farmaceuticas de moduladores de c-met. | |
| MX2016012103A (es) | Agonistas del receptor muscarinico. | |
| CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
| UY36075A (es) | Derivados de tubulisina | |
| GT201600017A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CR20150440A (es) | Nuevos derivados de piridina | |
| MX2015012833A (es) | Composiciones antibioticas de ceftolozano. | |
| CR20130569A (es) | Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo | |
| DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |